2. Immunology/Inflammation
  3. CD20
  4. Ofatumumab

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL).

For research use only. We do not sell to patients.

CAS No. : 679818-59-8

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Ofatumumab Featured Recommendations:

Ofatumumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL)[1][2][3].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Human
In Vitro

Ofatumumab (10 μg/mL; 6 h) significantly induces cell lysis in a complement-dependent cytotoxicity (CDC) assay of mantle cell lymphoma (MCL) cell lines, with an effect superior to that of Rituximab (HY-P9913), and is still active against resistant cells with low CD20 expression or high complement inhibitory protein (CD55/CD59) expression[1].
Ofatumumab (10 μg/mL; 24-72 h) has direct killing of B-cell lymphoma cell lines, with an inhibitory effect similar to that of Rituximab[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ofatumumab Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: Mantle cell lymphoma (MCL) cell lines (Granta, HBL-2, Jeko-1, Mino, Rec-1, Z-138)
Concentration: 10 μg/mL
Incubation Time: 6 h
Result: Cell Lysis : Induced higher CDC-mediated lysis compared to rituximab in all tested cell lines except Granta, with significant differences in Mino, Rec-1, and Jeko-1 cells. For example, in Mino cells, achieved 65% lysis vs. 35% with rituximab.
Resistance Mechanisms : Cells with high CD55/CD59 expression (e.g., Raji-4RH) showed reduced rituximab-induced lysis, but Ofatumumab maintained efficacy, indicating less dependency on CD20 density.

Cell Viability Assay[1]

Cell Line: B-cell lymphoma cell lines (Mino, Rec-1, HBL-2, Raji, RL)
Concentration: 10 μg/mL
Incubation Time: 24, 48, 72 h
Result: Cell Viability : Both antibodies caused time-dependent viability reduction, with Ofatumumab showing comparable activity to rituximab across most cell lines.
A significant difference was observed in Mino cells at 72 h, where Ofatumumab reduced viability to 30% vs. 45% with Rituximab.
Direct Cytotoxicity : Flow cytometry and immunofluorescence revealed no significant differences in apoptosis or cell cycle arrest between the two antibodies, suggesting minimal direct cytotoxic effects beyond immune-mediated lysis.
In Vivo

Ofatumumab (10 mg/kg; intravenous injection; days 0, 3, 7, and 10; 4 times in total) significantly delays tumor growth and prolongs mouse survival in the SCID mouse Z-138 cell subcutaneous xenograft tumor model, and its effect is superior to Rituximab (HY-P9913) (10 mg/kg)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female SCID mice (6-8 weeks old, ~20 g) + subcutaneous xenograft model of human mantle cell lymphoma (Z-138 cells)[1]
Dosage: 10 mg/kg (dissolved in sterile saline)
Administration: Intravenous injection via tail vein; 4 doses on days 0, 3, 7, and 10 post-tumor engraftment
Result: Significantly delayed early tumor progression compared to rituximab. Tumor volume in the ofatumumab group remained smaller than 500 mm3 for over 80 days, whereas the rituximab group showed progressive growth exceeding 2000 mm3 by day 120.
Resulted a median survival time of >90 days in the ofatumumab group (median not reached by study end), compared to 127 days in the Rituximab group.
Reduced tumor cellularity and increased apoptotic cells in of Atumumab-treated mice, with no evidence of treatment-related organ toxicity.
Clinical Trial
Molecular Weight

145940.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Ofatumumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Ofatumumab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 24.00 and 25.15 ng/mL.
Purity & Documentation

Purity: ≥99.0%

SDS (251 KB)

COA (231 KB) SDS-PAGE (144 KB) SEC-HPLC (126 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ofatumumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ofatumumab679818-59-8CD20anti-CD20 monoclonal antibodyselectivecytotoxicitylysing B cellschronic lymphocytic leukaemiaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ofatumumab
Cat. No.:
HY-P9961
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.